CoChat

Antagonizing Integrin β3 Increases Immunosuppression in Cancer

Open access
Su, Xinming, Esser, Alison K., Amend, Sarah R., Xiang, Jingyu, Xu, Yalin, Ross, Michael H., Fox, Gregory C., Kobayashi, Takayuki, Steri, Veronica, Roomp, Kirsten, Fontana, Francesca, Hurchla, Michelle A., Knolhoff, Brett L., Meyer, Melissa A., Morgan, Elizabeth A., Tomasson, Julia C., Novack, Joshua S., Zou, Wei, Faccio, Roberta, Novack, Deborah V., Robinson, Stephen D., Teitelbaum, Steven L., DeNardo, David G., Schneider, Jochen G., Weilbaecher, Katherine N. · 2016 · Cancer Research
Cited by 88

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Integrin β3 is critical for tumor invasion, neoangiogenesis, and inflammation, making it a promising cancer target. However, preclinical and clinical data of integrin β3 antagonists have demonstrated no benefit or worse outcomes. We hypothesized that integrin β3 could affect tumor immunity and evaluated tumors in mice with deletion of integrin β3 in macrophage lineage cells (β3KOM). β3KOM mice had increased melanoma and breast cancer growth with increased tumor-promoting M2 macrophages and decreased CD8+ T cells. Integrin β3 antagonist, cilengitide, also enhanced tumor growth and increased M2 function. We uncovered a negative feedback loop in M2 myeloid cells, wherein integrin β3 signaling favored STAT1 activation, an M1-polarizing signal, and suppressed M2-polarizing STAT6 activation. Finally, disruption of CD8+ T cells, macrophages, or macrophage integrin β3 signaling blocked the tumor-promoting effects of integrin β3 antagonism. These results suggest that effects of integrin β3 therapies on immune cells should be considered to improve outcomes. Cancer Res; 76(12); 3484–95. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-2663

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 88

Metadata

Authors
Su, X., Esser, A. K., Amend, S. R., Xiang, J., Xu, Y., Ross, M. H., Fox, G. C., Kobayashi, T., Steri, V., Roomp, K., Fontana, F., Hurchla, M. A., Knolhoff, B. L., Meyer, M. A., Morgan, E. A., Tomasson, J. C., Novack, J. S., Zou, W., Faccio, R., Novack, D. V., Robinson, S. D., Teitelbaum, S. L., DeNardo, D. G., Schneider, J. G., & Weilbaecher, K. N.
Venue
Cancer Research
Published
2016-06-14
Volume
76
Issue
12
Pages
3484-3495
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2417740873
Cited by
88
References
9
FWCI
3.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antagonizing Integrin β3 Increases Immunosuppression in Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2663
The paper
Su, X., Esser, A. K., Amend, S. R., Xiang, J., Xu, Y., Ross, M. H., Fox, G. C., Kobayashi, T., Steri, V., Roomp, K., Fontana, F., Hurchla, M. A., Knolhoff, B. L., Meyer, M. A., Morgan, E. A., Tomasson, J. C., Novack, J. S., Zou, W., Faccio, R., . . . Weilbaecher, K. N. (2016). Antagonizing Integrin β3 Increases Immunosuppression in Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2663

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.